Demographic and Clinical characteristics |
Patients (n = 60) |
Control subjects
(n = 40) |
P1-value |
P2-value |
P3-value |
Patients with migraine |
Patients with TTH |
| Male/female; # (%) |
22/38 |
1/3 |
12/28 |
- |
- |
- |
| Age; years |
32.0-55.0 (47.83 ± 7.31) |
32.0-55.0 (48.55 ± 7.60) |
35.55-55.00 (48.35 ± 7.60) |
0.494 |
0.345 |
0.255 |
Patients with episodic migraine; # (%)
MoA
MA
Patients with chronic migraine; # (%)
Patients with TTH; # (%)
Duration of migraine; years
Duration of episodic migraine; years
Duration of chronic migraine; years
Duration of TTH; years |
35 (62.5%)
25 (44.64%)
10 (17.86%)
21 (37.5%)
4 (6.67%)
1.00-22.00 (8.528 ± 4.27)
2.0-18.0 (6.56 ± 1.45)
1.00-22.00 (9.328 ± 4.27)
- |
-
-
-
-
-
-
-
-
5.0-20.0 (15.34 ± 6.33) |
9 (22.5 %)
5(12.5%)
3 (7.5%)
1 (2.5%)
11 (27.5%)
5.00-9.00 (3.325 ± 1.05)
-
-
3.0-15.0 (12.23 ± 4.55) |
-
-
-
-
-
-
-
-
- |
-
-
-
-
-
-
-
-
0.255 |
-
-
-
-
-
-
-
-
0.012 |
Frequency of headache attacks; #/month (%)
Low-frequency (<4/month)
High-frequency (≥4/month) |
5 (8.33%)
51 (85%) |
1 (1.67%)
3 (5%) |
4 (10%)
2 (5%) |
-
- |
-
- |
-
- |
| BMI; kg/m2 |
29.07-55.55 (39.01 ± 6.05) |
29.07-55.55(28.55 ± 6.56) |
26.20-53.50 (30.52 ± 4.59) |
0.253 |
0.865 |
0.365 |
Degree of obesity; # (%)
normal: 18.5-24.9 kg/m2
Overweight: 25.0-29.9 kg/m2
Obese: 30.0-34.9 kg/m2
Morbidly obese: >35.0 kg/m2 |
0
2 (3.33%)
21 (35%)
33 (55%) |
0
3 (5%)
1 (1.67%)
0 |
14 (35%)
16 (40%)
2 (5%)
0 |
-
-
-
- |
-
-
-
- |
-
-
-
- |
| WC; cm |
93.0-136.0 (126.27 ± 9.84) |
93.0-136.0 (108.36 ± 9.99) |
100.0-132.0 (87.05 ± 5.32) |
0.050 |
0.053 |
0.058 |
SBP; mmHg
DBP; mmHg |
110.0-180.0 (150.92 ± 16.86)
70.0-110.0 (105.75 ± 6.56) |
100.0-150.0 (135.060 ± 16.33)
70.0-100.0 (80.20 ± 8.10) |
100.0-130.0 (120.0 ± 0.0)
60.0-85.0 (80.0 ± 0.0) |
0.052
0.054 |
0.432
0.405 |
0.052
0.050 |
Duration of T2DM; years
Duration of obesity; years
Duration of HTN; years |
2.0-20.0 (5.98 ± 3.60)
2.0-20.0 (8.75 ± 4.47)
1.0-18.0 (5.12 ± 3.44) |
2.0-20.0 (6.24 ± 2.50)
2.0-20.0 (5.04 ± 2.08)
1.0-18.0 (4.92 ± 2.16) |
-
-
- |
-
-
- |
-
0.057
- |
-
-
- |
Degree of control on anti-diabetics treatment
Controlled; # (%)
Uncontrolled; # (%)
Degree of control on anti-hypertensive treatment
Controlled; # (%)
Uncontrolled; # (%)
Degree of control on lipid lowering treatment
Controlled; # (%)
Uncontrolled; # (%) |
23 (38.33%)
33 (55%)
24 (40%)
32 (53.33%)
23 (38.33%)
33 (55%) |
3 (5%)
1 (1.67%)
2 (3.33%)
2 (3.33%)
4 (6.67%)
0 |
-
-
-
-
-
- |
-
-
-
-
-
- |
-
-
-
-
-
- |
-
-
-
-
-
- |
